RU2016118753A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016118753A3 RU2016118753A3 RU2016118753A RU2016118753A RU2016118753A3 RU 2016118753 A3 RU2016118753 A3 RU 2016118753A3 RU 2016118753 A RU2016118753 A RU 2016118753A RU 2016118753 A RU2016118753 A RU 2016118753A RU 2016118753 A3 RU2016118753 A3 RU 2016118753A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310512377 | 2013-10-25 | ||
| CN201310512377.0 | 2013-10-25 | ||
| PCT/CN2014/085976 WO2015058589A1 (zh) | 2013-10-25 | 2014-09-05 | 吡啶酮类衍生物、其制备方法及其在医药上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016118753A RU2016118753A (ru) | 2017-11-29 |
| RU2016118753A3 true RU2016118753A3 (ru) | 2018-05-25 |
| RU2667892C2 RU2667892C2 (ru) | 2018-09-25 |
Family
ID=52992223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016118753A RU2667892C2 (ru) | 2013-10-25 | 2014-09-05 | Производные пиридилкетона, способ их получения и их фармацевтическое применение |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9914703B2 (ru) |
| EP (1) | EP3061747B1 (ru) |
| JP (1) | JP6403172B2 (ru) |
| KR (1) | KR102222569B1 (ru) |
| CN (1) | CN104936945B (ru) |
| AU (1) | AU2014339527B2 (ru) |
| BR (1) | BR112016007396B1 (ru) |
| CA (1) | CA2927635C (ru) |
| ES (1) | ES2868450T3 (ru) |
| HK (1) | HK1212980A1 (ru) |
| MX (1) | MX2016004742A (ru) |
| PL (1) | PL3061747T3 (ru) |
| PT (1) | PT3061747T (ru) |
| RU (1) | RU2667892C2 (ru) |
| TW (1) | TWI662026B (ru) |
| WO (1) | WO2015058589A1 (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3275866B1 (en) * | 2015-03-27 | 2019-12-04 | Jiangsu Hengrui Medicine Co., Ltd. | P-toluenesulfonate for mek kinase inhibitor, and crystal form thereof and preparation method therefor |
| CN104892499B (zh) * | 2015-06-26 | 2017-07-21 | 江西省科学院应用化学研究所 | 一种2‑吡啶酮类衍生物的合成方法 |
| US10709699B2 (en) * | 2016-11-25 | 2020-07-14 | Jiangsu Hengrui Medicine Co., Ltd. | Pyridone derivative pharmaceutical composition and preparation method thereof |
| CN108884048B (zh) * | 2016-12-01 | 2021-07-27 | 江苏恒瑞医药股份有限公司 | 一种吡啶酮类衍生物的制备方法及其中间体 |
| CN108314645A (zh) * | 2017-01-18 | 2018-07-24 | 上海映诺济生物科技有限公司 | 一类具有抗细胞增殖活性的化合物、制备方法和用途 |
| CN111201225B (zh) | 2017-06-23 | 2021-11-05 | 基石药业 | 作为mek抑制剂的类香豆素环类化合物及其应用 |
| CN112912380B (zh) * | 2018-12-21 | 2023-08-11 | 基石药业（苏州）有限公司 | 一种mek抑制剂的晶型、无定形及其应用 |
| WO2020156162A1 (zh) * | 2019-01-29 | 2020-08-06 | 贝达药业股份有限公司 | Mek抑制剂及其在医药上的应用 |
| CN111514140B (zh) * | 2019-02-01 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| TW202114994A (zh) * | 2019-07-29 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種１，６－二氫吡啶－３－甲醯胺衍生物的製備方法 |
| TW202114667A (zh) * | 2019-09-11 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | Mek抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤的藥物中的用途 |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| AR121078A1 (es) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN111848613B (zh) * | 2020-08-11 | 2021-09-24 | 山东大学 | 一种二芳基嘧啶骈吡啶酮类衍生物及其制备方法与应用 |
| KR102494188B1 (ko) * | 2021-04-14 | 2023-01-31 | 시오노기 앤드 컴파니, 리미티드 | 바이러스 증식 저해 작용을 갖는 트라이아진 유도체 및 그들을 함유하는 의약 조성물 |
| CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
| WO2023230205A1 (en) * | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002354575A1 (en) * | 2001-07-12 | 2003-01-29 | Bristol-Myers Squibb Pharma Company | Tetrahydropurinones as corticotropin releasing factor |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| CN101912400B (zh) * | 2004-06-11 | 2013-06-26 | 日本烟草产业株式会社 | 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物 |
| CA2608201C (en) * | 2005-05-18 | 2013-12-31 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
| US7612212B2 (en) * | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| CN101389609B (zh) * | 2006-02-22 | 2012-01-11 | 霍夫曼-拉罗奇有限公司 | 基于乙内酰脲的激酶抑制剂 |
| KR20110028376A (ko) | 2008-07-01 | 2011-03-17 | 제넨테크, 인크. | Ｍｅｋ 키나제 억제제로서의 이소인돌론 유도체 및 사용 방법 |
| CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
| US20120238599A1 (en) * | 2011-03-17 | 2012-09-20 | Chemizon, A Division Of Optomagic Co., Ltd. | Heterocyclic compounds as mek inhibitors |
| EP2714039A1 (en) * | 2011-05-23 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
| WO2013136254A1 (en) * | 2012-03-14 | 2013-09-19 | Lupin Limited | Heterocyclyl compounds |
-
2014
- 2014-09-05 CA CA2927635A patent/CA2927635C/en not_active Expired - Fee Related
- 2014-09-05 AU AU2014339527A patent/AU2014339527B2/en not_active Ceased
- 2014-09-05 KR KR1020167012819A patent/KR102222569B1/ko active IP Right Grant
- 2014-09-05 PL PL14854930T patent/PL3061747T3/pl unknown
- 2014-09-05 CN CN201480003661.8A patent/CN104936945B/zh active Active
- 2014-09-05 RU RU2016118753A patent/RU2667892C2/ru active
- 2014-09-05 WO PCT/CN2014/085976 patent/WO2015058589A1/zh active Application Filing
- 2014-09-05 ES ES14854930T patent/ES2868450T3/es active Active
- 2014-09-05 BR BR112016007396-7A patent/BR112016007396B1/pt not_active IP Right Cessation
- 2014-09-05 PT PT148549306T patent/PT3061747T/pt unknown
- 2014-09-05 JP JP2016518444A patent/JP6403172B2/ja not_active Expired - Fee Related
- 2014-09-05 US US15/030,125 patent/US9914703B2/en active Active
- 2014-09-05 EP EP14854930.6A patent/EP3061747B1/en active Active
- 2014-09-05 MX MX2016004742A patent/MX2016004742A/es unknown
- 2014-09-25 TW TW103133170A patent/TWI662026B/zh not_active IP Right Cessation
-
2016
- 2016-01-29 HK HK16101027.7A patent/HK1212980A1/zh not_active IP Right Cessation
-
2017
- 2017-09-28 US US15/719,138 patent/US10064848B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US10064848B2 (en) | 2018-09-04 |
| EP3061747A4 (en) | 2017-05-10 |
| EP3061747A1 (en) | 2016-08-31 |
| CA2927635C (en) | 2021-07-20 |
| WO2015058589A1 (zh) | 2015-04-30 |
| MX2016004742A (es) | 2016-12-09 |
| CN104936945B (zh) | 2017-11-03 |
| AU2014339527A1 (en) | 2016-05-12 |
| CA2927635A1 (en) | 2015-04-30 |
| PT3061747T (pt) | 2021-05-04 |
| BR112016007396B1 (pt) | 2021-01-19 |
| EP3061747B1 (en) | 2021-04-07 |
| ES2868450T3 (es) | 2021-10-21 |
| US20160244410A1 (en) | 2016-08-25 |
| JP2016534027A (ja) | 2016-11-04 |
| US9914703B2 (en) | 2018-03-13 |
| KR20160074554A (ko) | 2016-06-28 |
| AU2014339527B2 (en) | 2018-07-19 |
| HK1212980A1 (zh) | 2016-06-24 |
| US20180016236A1 (en) | 2018-01-18 |
| RU2016118753A (ru) | 2017-11-29 |
| TWI662026B (zh) | 2019-06-11 |
| CN104936945A (zh) | 2015-09-23 |
| KR102222569B1 (ko) | 2021-03-05 |
| JP6403172B2 (ja) | 2018-10-10 |
| TW201518278A (zh) | 2015-05-16 |
| RU2667892C2 (ru) | 2018-09-25 |
| BR112016007396A2 (pt) | 2017-08-01 |
| PL3061747T3 (pl) | 2021-07-19 |